More Patients Set to Benefit as Kanghong Pharmaceutical Targets New Indications with Conbercept
News provided by
Share this article
Share this article
CHENGDU, China, Feb. 3, 2021 /PRNewswire/ Chengdu Kanghong Pharmaceutical Group ( Kanghong , SHE: 002773), has received Special Protocol Assessments from the Food and Drug Administration for three new indications for its biologic drug conbercept. The drug is an anti-VEGF fusion protein, approved and marketed in China as Lumitin
®, for the treatment of retinal diseases.
Conbercept is given through intravitreal injection.
Conbercept has a VEGF-R2 kinase insert domain receptor (KDR) Ig-like region 4 (KDRd4), improving the three-dimensional structure and efficiency of dimer formation, thereby increasing the binding capacity of conbercept to VEGF.
Press release content from PR Newswire. The AP news staff was not involved in its creation.
Conbercept: New Generation of Product for Treatment of nAMD Completes 36-week Primary Endpoint Visits of Phase III Trial
December 23, 2020 GMT
CHENGDU, China, Dec. 23, 2020 /PRNewswire/ Chengdu Kanghong Pharmaceutical Group (“Kanghong”) announced a key development milestone of its key product conbercept last month. Kanghong is seeking global approval of conbercept by undertaking a multicenter, multinational, double-masked, parallel-group, dose-ranging, active-controlled, randomized trial (nicknamed “PANDA”) to test the efficacy and safety of conbercept intravitreal injection in the treatment of neovascular age-related macular degeneration (“nAMD”). PANDA trials recently reached an important milestone by completing 36-week primary endpoint visits of enrolled patients. Conbercept is expected to launch globally in 2023, bringing a new treatment option to patients.